Alendronic acid

Generic Name: Alendronic acid

Brand Names: Adrovance, Binosto, Fosamax, Fosamax Plus D, Fosavance

Drug Type: Small Molecule

Chemical Formula: C_₄H_₁₃NO_₇P_₂

CAS Number: 66376-36-1

Unique Ingredient Identifier: X1J18R4W8P

Background: Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.

Indication: Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min.

Associated Conditions: Osteogenesis Imperfecta (OI), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget’s Disease

Associated Therapies: -

Clinical Trials

99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis

Not Applicable

Completed

Conditions: Differentiated Thyroid Cancer
Osteoporosis

Interventions: Drug: 99Tc-MDP
Drug: Fosamax

First Posted Date: 2014-12-02

Last Posted Date: 2021-11-17

Lead Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 142

Registration Number: NCT02304757

Locations: 🇨🇳
Nuclear Medicine Xinhua Hospital, Shanghai, Shanghai, China

Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta

Phase 4

Completed

Conditions: Osteogenesis Imperfecta

Interventions: Drug: Alendronate

First Posted Date: 2014-12-01

Last Posted Date: 2014-12-10

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 99

Registration Number: NCT02303873

Alendronate to Prevent Loss of Bronchoprotection in Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: Alendronate

First Posted Date: 2014-09-03

Last Posted Date: 2018-01-12

Lead Sponsor: Milton S. Hershey Medical Center

Target Recruit Count: 78

Registration Number: NCT02230332

Locations: 🇺🇸
University of Arizona College of Medicine, Tucson, Arizona, United States
🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸
University of California - San Francisco, San Francisco, California, United States

and more 7 locations

Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide

Phase 2

Completed

Conditions: Bone Loss
Osteoporosis
Spinal Cord Injury

Interventions: Drug: Alendronate
Dietary Supplement: Calcium
Dietary Supplement: Vitamin D

First Posted Date: 2014-07-21

Last Posted Date: 2023-03-30

Lead Sponsor: Northwestern University

Target Recruit Count: 17

Registration Number: NCT02195895

Locations: 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

1% Alendronate Gel in Treatment of Chronic Periodontitis Among Smokers

Phase 2

Completed

Conditions: Chronic Periodontitis

Interventions: Drug: Placebo
Drug: Alendronate

First Posted Date: 2014-06-20

Last Posted Date: 2014-06-20

Lead Sponsor: Government Dental College and Research Institute, Bangalore

Target Recruit Count: 46

Registration Number: NCT02168543

Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study

Phase 4

Completed

Conditions: Osteoporosis

Interventions: Drug: Alendronate

First Posted Date: 2014-05-15

Last Posted Date: 2017-05-12

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 27

Registration Number: NCT02139007

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis.

Phase 2

Completed

Conditions: Calcific Aortic Stenosis

Interventions: Drug: Alendronic Acid Placebo
Drug: Alendronic Acid
Drug: Denosumab
Drug: Denosumab Placebo

First Posted Date: 2014-05-06

Last Posted Date: 2021-10-14

Lead Sponsor: University of Edinburgh

Target Recruit Count: 152

Registration Number: NCT02132026

Locations: 🇬🇧
Clinical Research Facility University of Edinburgh, Edinburgh, United Kingdom

The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults

Phase 1

Completed

Conditions: Hepatitis B

Interventions: Drug: Hepatitis B Vaccine
Drug: Alendronate
Drug: Placebo

First Posted Date: 2014-02-07

Last Posted Date: 2016-10-21

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 28

Registration Number: NCT02057263

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Treatment of Low Bone Density in Cystic Fibrosis.

Phase 3

Completed

Conditions: Osteoporosis
Cystic Fibrosis

Interventions: Drug: Placebo
Drug: Alendronate

First Posted Date: 2013-03-18

Last Posted Date: 2014-03-06

Lead Sponsor: Istituto Auxologico Italiano

Target Recruit Count: 171

Registration Number: NCT01812551

Locations: 🇮🇹
CRR Fibrosi Cistica, Unità Operativa di Pediatria, Ospedale Misericordia, Grosseto, Italy
🇮🇹
CRR Fibrosi Cistica, Clinica Pediatrica, Policlinico Universitario di Messina, Messina, Italy
🇮🇹
CRR Fibrosi Cistica, Dipartimento Pediatria, Università Federico II, Napoli, Italy

and more 8 locations

RA Denosumab on Bone Microstructure Study

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Alendronate
Drug: Denosumab

First Posted Date: 2013-01-17

Last Posted Date: 2014-09-11

Lead Sponsor: Chinese University of Hong Kong

Target Recruit Count: 40

Registration Number: NCT01770106

Locations: 🇭🇰
Prince of Wales Hospital, Shatin, N.t., Hong Kong

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy